sunitinib Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
tyrosine kinase inhibitors 2544 557795-19-4

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • sunitinib
  • sunitinib malate
  • sutent
  • SU-011248
  • SU-010398
  • PHA-290940AD
An indole and pyrrole derivative that inhibits VEGFR-2 and PDGFR BETA RECEPTOR TYROSINE KINASES. It is used as an antineoplastic agent for the treatment of GASTROINTESTINAL STROMAL TUMORS, and for treatment of advanced or metastatic RENAL CELL CARCINOMA.
  • Molecular weight: 398.48
  • Formula: C22H27FN4O2
  • CLOGP: 3
  • LIPINSKI: 0
  • HAC: 6
  • HDO: 3
  • TPSA: 77.23
  • ALOGS: -4.11
  • ROTB: 7

  • Status: ONP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 25 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 4 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 1.34 ┬ÁM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 54.50 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Approvals:

DateAgencyCompanyOrphan
July 19, 2006 EMA
Jan. 26, 2006 FDA CPPI CV

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Disease progression 2464.32 39.00 665 5739 16430 2335251
Diarrhoea 1906.44 39.00 810 5594 82754 2268927
Fatigue 1724.36 39.00 759 5645 84114 2267567
Death 1343.40 39.00 632 5772 80836 2270845
Palmar-plantar erythrodysaesthesia syndrome 1236.32 39.00 291 6113 3910 2347771
Nausea 1230.92 39.00 660 5744 111529 2240152
Stomatitis 1106.29 39.00 316 6088 9394 2342287
Vomiting 1004.70 39.00 499 5905 71103 2280578
Neoplasm progression 972.42 39.00 245 6159 4423 2347258
Hypertension 963.08 39.00 366 6038 26995 2324686
Thrombocytopenia 945.49 39.00 329 6075 18802 2332879
Decreased appetite 890.36 39.00 351 6053 28540 2323141
Asthenia 882.52 39.00 401 6003 46525 2305156
Dysgeusia 845.71 39.00 249 6155 8210 2343471
Oral pain 826.12 39.00 202 6202 3195 2348486
Renal cell carcinoma 792.75 39.00 150 6254 607 2351074
Platelet count decreased 707.73 39.00 253 6151 15560 2336121
Hypothyroidism 690.33 39.00 185 6219 4272 2347409
Metastatic renal cell carcinoma 635.81 39.00 106 6298 155 2351526
Dehydration 568.48 39.00 237 6167 22058 2329623
Yellow skin 476.82 39.00 92 6312 420 2351261
Renal cancer 467.98 39.00 95 6309 589 2351092
Blood pressure increased 467.87 39.00 191 6213 16795 2334886
Gastrointestinal stromal tumour 449.06 39.00 80 6324 209 2351472
Mucosal inflammation 427.25 39.00 132 6272 5092 2346589
Weight decreased 376.95 39.00 192 6212 28179 2323502
Hair colour changes 368.42 39.00 71 6333 321 2351360
Anaemia 362.03 39.00 200 6204 34592 2317089
Glossodynia 344.87 39.00 90 6314 1855 2349826
Blister 342.60 39.00 119 6285 6652 2345029
Pleural effusion 340.78 39.00 137 6267 11531 2340150
Pain in extremity 337.50 39.00 205 6199 42335 2309346
Dyspepsia 334.55 39.00 129 6275 9715 2341966
Epistaxis 331.80 39.00 128 6276 9651 2342030
Malaise 310.83 39.00 215 6189 55370 2296311
General physical health deterioration 299.09 39.00 132 6272 14007 2337674
Constipation 294.58 39.00 149 6255 21480 2330201
Neutropenia 283.41 39.00 145 6259 21403 2330278
White blood cell count decreased 282.21 39.00 137 6267 18071 2333610
Dry skin 276.20 39.00 101 6303 6551 2345130
Abdominal pain 265.46 39.00 163 6241 34211 2317470
Renal cancer metastatic 249.12 39.00 42 6362 68 2351613
Headache 245.00 39.00 217 6187 79962 2271719
Ageusia 230.75 39.00 66 6338 1932 2349749
Pancytopenia 229.48 39.00 103 6301 11349 2340332
Skin discolouration 227.56 39.00 83 6321 5337 2346344
Pain 224.63 39.00 185 6219 61672 2290009
Dry mouth 220.51 39.00 91 6313 8162 2343519
Pyrexia 216.92 39.00 171 6233 53537 2298144
Rash 207.58 39.00 174 6230 59384 2292297
Ascites 206.34 39.00 78 6326 5542 2346139
Skin exfoliation 204.08 39.00 78 6326 5712 2345969
Toxicity to various agents 199.84 39.00 134 6270 32620 2319061
Dyspnoea 195.54 39.00 190 6214 78543 2273138
Product use issue 174.68 39.00 87 6317 12082 2339599
Abdominal discomfort 171.82 39.00 97 6307 17359 2334322
Bone marrow failure 170.01 39.00 68 6336 5618 2346063
Confusional state 163.92 39.00 106 6298 24238 2327443
Hyponatraemia 161.49 39.00 85 6319 13240 2338441
Haemoglobin decreased 155.06 39.00 92 6312 18059 2333622
Oedema peripheral 149.05 39.00 99 6305 23664 2328017
Flatulence 148.86 39.00 58 6346 4467 2347214
Urinary tract infection 146.31 39.00 107 6297 29835 2321846
Hyperkeratosis 145.84 39.00 38 6366 775 2350906
Oral discomfort 145.75 39.00 42 6362 1261 2350420
Alopecia 143.66 39.00 94 6310 21907 2329774
Second primary malignancy 142.45 39.00 39 6365 967 2350714
Leukopenia 140.70 39.00 71 6333 10125 2341556
Dizziness 140.49 39.00 139 6265 58526 2293155
Gastrooesophageal reflux disease 139.33 39.00 68 6336 9027 2342654
Blood thyroid stimulating hormone increased 138.15 39.00 38 6366 959 2350722
Malignant neoplasm progression 137.44 39.00 74 6330 12054 2339627
Gait disturbance 131.96 39.00 90 6314 22455 2329226
Abdominal pain upper 131.19 39.00 89 6315 22011 2329670
Oedema 126.18 39.00 66 6338 10137 2341544
Product use in unapproved indication 123.16 39.00 67 6337 11133 2340548
Neoplasm malignant 118.69 39.00 51 6353 5042 2346639
Jaundice 118.08 39.00 52 6352 5456 2346225
Haemorrhage 115.76 39.00 64 6340 10975 2340706
Cardiac failure 115.65 39.00 66 6338 12028 2339653
Renal failure 115.33 39.00 75 6329 17274 2334407
Acute kidney injury 114.13 39.00 90 6314 28032 2323649
Blood creatinine increased 113.01 39.00 62 6342 10471 2341210
Back pain 110.94 39.00 93 6311 31566 2320115
Erythema 109.64 39.00 84 6320 25075 2326606
Peripheral swelling 109.50 39.00 73 6331 17524 2334157
Hypotension 108.97 39.00 93 6311 32343 2319338
Thyroid disorder 108.64 39.00 35 6369 1538 2350143
Pneumonia 107.26 39.00 111 6293 49185 2302496
Disseminated intravascular coagulation 103.34 39.00 41 6363 3309 2348372
Eating disorder 99.63 39.00 36 6368 2245 2349436
Cough 95.33 39.00 87 6317 33030 2318651
Dysphagia 94.11 39.00 59 6345 12746 2338935
Abdominal distension 92.03 39.00 54 6350 10357 2341324
Tongue discomfort 90.74 39.00 21 6383 255 2351426
Metastases to liver 90.73 39.00 36 6368 2905 2348776
Mouth ulceration 90.57 39.00 39 6365 3873 2347808
Proteinuria 88.32 39.00 35 6369 2815 2348866
Generalised oedema 86.85 39.00 33 6371 2370 2349311
Chromaturia 85.98 39.00 34 6370 2719 2348962
Gingival pain 85.85 39.00 27 6377 1096 2350585
Osteonecrosis of jaw 85.56 39.00 47 6357 7949 2343732
Blood lactate dehydrogenase increased 84.83 39.00 36 6368 3448 2348233
Fall 84.78 39.00 96 6308 47003 2304678
Pulmonary embolism 84.54 39.00 63 6341 18020 2333661
Gingival bleeding 84.42 39.00 31 6373 2024 2349657
Haematuria 83.69 39.00 38 6366 4280 2347401
Insomnia 82.62 39.00 72 6332 25715 2325966
Haematochezia 79.27 39.00 39 6365 5256 2346425
Gastrointestinal haemorrhage 78.31 39.00 52 6352 12383 2339298
Face oedema 77.32 39.00 35 6369 3913 2347768
Weight increased 76.89 39.00 65 6339 22272 2329409
Pericardial effusion 76.81 39.00 35 6369 3974 2347707
Skin lesion 76.67 39.00 35 6369 3990 2347691
Syncope 74.89 39.00 57 6347 16818 2334863
Hypertensive crisis 74.87 39.00 30 6374 2483 2349198
Muscle spasms 74.73 39.00 63 6341 21503 2330178
Pruritus 74.02 39.00 86 6318 43254 2308427
Aspartate aminotransferase increased 72.87 39.00 50 6354 12562 2339119
Drug intolerance 71.37 39.00 51 6353 13666 2338015
Multiple organ dysfunction syndrome 71.13 39.00 41 6363 7600 2344081
Hepatic failure 70.85 39.00 37 6367 5652 2346029
Hypophagia 70.63 39.00 33 6371 3967 2347714
Sepsis 70.29 39.00 57 6347 18431 2333250
Petechiae 69.67 39.00 27 6377 2045 2349636
Loss of consciousness 69.54 39.00 57 6347 18710 2332971
Metastases to central nervous system 68.72 39.00 27 6377 2121 2349560
Swelling face 67.87 39.00 43 6361 9450 2342231
Oral mucosal blistering 66.68 39.00 21 6383 856 2350825
Pancreatic neuroendocrine tumour 66.66 39.00 13 6391 63 2351618
Mental status changes 65.81 39.00 35 6369 5547 2346134
Respiratory failure 65.15 39.00 48 6356 13480 2338201
Feeding disorder 63.62 39.00 23 6381 1435 2350246
Cerebral haemorrhage 63.45 39.00 34 6370 5470 2346211
Hyperaesthesia 63.33 39.00 22 6382 1221 2350460
Tongue disorder 61.58 39.00 21 6383 1102 2350579
Skin ulcer 61.06 39.00 30 6374 4029 2347652
Muscular weakness 61.03 39.00 48 6356 14849 2336832
Bone pain 59.98 39.00 39 6365 8957 2342724
Cardiac failure congestive 59.84 39.00 49 6355 16052 2335629
Periorbital oedema 59.61 39.00 20 6384 998 2350683
Hypocalcaemia 59.31 39.00 29 6375 3854 2347827
Lethargy 58.58 39.00 38 6366 8692 2342989
Somnolence 58.51 39.00 57 6347 23428 2328253
Oropharyngeal pain 58.02 39.00 42 6362 11476 2340205
Burning sensation 57.31 39.00 36 6368 7792 2343889
Condition aggravated 57.15 39.00 65 6339 31914 2319767
Alanine aminotransferase increased 57.02 39.00 45 6359 13987 2337694
Tumour haemorrhage 56.08 39.00 15 6389 339 2351342
Intestinal perforation 55.50 39.00 22 6382 1769 2349912
Haematemesis 55.00 39.00 28 6376 4054 2347627
Colitis 53.91 39.00 30 6374 5196 2346485
Eyelid oedema 53.70 39.00 24 6380 2602 2349079
Blood count abnormal 53.63 39.00 23 6381 2259 2349422
Hypoalbuminaemia 53.47 39.00 20 6384 1374 2350307
Rectal haemorrhage 53.37 39.00 31 6373 5825 2345856
Chest pain 53.36 39.00 59 6345 28078 2323603
Impaired healing 52.94 39.00 30 6374 5381 2346300
Hyperthyroidism 52.14 39.00 22 6382 2075 2349606
Blood glucose decreased 51.81 39.00 25 6379 3227 2348454
Liver function test abnormal 51.23 39.00 33 6371 7457 2344224
Myocardial infarction 50.85 39.00 48 6356 18965 2332716
Eye swelling 50.26 39.00 27 6377 4363 2347318
Nephrotic syndrome 50.05 39.00 18 6386 1106 2350575
Hepatic enzyme increased 49.95 39.00 36 6368 9766 2341915
Faeces discoloured 49.65 39.00 22 6382 2337 2349344
Myalgia 49.63 39.00 52 6352 23281 2328400
Bradycardia 49.36 39.00 36 6368 9945 2341736
Glossitis 49.33 39.00 15 6389 543 2351138
Ejection fraction decreased 49.11 39.00 23 6381 2778 2348903
Lipase increased 48.97 39.00 19 6385 1443 2350238
Lacrimation increased 48.88 39.00 23 6381 2807 2348874
Arthralgia 48.84 39.00 79 6325 54206 2297475
Posterior reversible encephalopathy syndrome 48.60 39.00 22 6382 2458 2349223
Dysphonia 48.43 39.00 30 6374 6334 2345347
Skin fissures 48.17 39.00 18 6386 1233 2350448
Thyroid function test abnormal 48.09 39.00 15 6389 592 2351089
Off label use 48.01 39.00 93 6311 73505 2278176
Blood bilirubin increased 47.93 39.00 28 6376 5317 2346364
Rash macular 46.93 39.00 24 6380 3507 2348174
Blood sodium decreased 46.88 39.00 23 6381 3077 2348604
Musculoskeletal pain 46.74 39.00 36 6368 10794 2340887
Cerebrovascular accident 46.57 39.00 47 6357 20139 2331542
Soft tissue sarcoma 46.25 39.00 9 6395 43 2351638
Metastases to lung 45.86 39.00 19 6385 1712 2349969
Purpura 45.04 39.00 19 6385 1791 2349890
Chills 44.94 39.00 41 6363 15511 2336170
Blood glucose increased 44.81 39.00 37 6367 12253 2339428
Peritonitis 44.70 39.00 21 6383 2553 2349128
Renal impairment 44.55 39.00 34 6370 10058 2341623
Blood pressure fluctuation 44.39 39.00 19 6385 1856 2349825
Renal disorder 44.22 39.00 25 6379 4463 2347218
Skin toxicity 44.20 39.00 15 6389 775 2350906
Plantar erythema 44.11 39.00 9 6395 57 2351624
Feeling abnormal 43.93 39.00 49 6355 23532 2328149
Blood test abnormal 43.68 39.00 17 6387 1301 2350380
Proctalgia 42.72 39.00 14 6390 649 2351032
Skin disorder 40.64 39.00 22 6382 3609 2348072
Mouth haemorrhage 40.60 39.00 15 6389 995 2350686
Blood alkaline phosphatase increased 40.28 39.00 27 6377 6518 2345163
Hepatic function abnormal 39.59 39.00 26 6378 6066 2345615
Contusion 39.43 39.00 35 6369 12775 2338906
Intestinal obstruction 39.35 39.00 23 6381 4370 2347311

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Disease progression 4841.51 41.31 1428 10025 15835 1719493
Death 2492.21 41.31 1392 10061 86051 1649277
Diarrhoea 2369.91 41.31 1151 10302 52701 1682627
Fatigue 2178.87 41.31 1068 10385 49713 1685615
Palmar-plantar erythrodysaesthesia syndrome 1812.19 41.31 473 10980 3034 1732294
Neoplasm progression 1733.01 41.31 450 11003 2817 1732511
Renal cell carcinoma 1663.17 41.31 375 11078 1133 1734195
Dysgeusia 1342.18 41.31 405 11048 4644 1730684
Decreased appetite 1308.16 41.31 598 10855 23273 1712055
Hypertension 1239.86 41.31 542 10911 18906 1716422
Nausea 1228.22 41.31 736 10717 50460 1684868
Metastatic renal cell carcinoma 1190.03 41.31 243 11210 368 1734960
Renal cancer 1157.00 41.31 263 11190 828 1734500
Asthenia 1135.66 41.31 612 10841 34058 1701270
Stomatitis 1048.55 41.31 341 11112 5063 1730265
Thrombocytopenia 862.03 41.31 434 11019 20815 1714513
Platelet count decreased 846.21 41.31 396 11057 16127 1719201
Vomiting 810.35 41.31 510 10943 37805 1697523
Oral pain 742.02 41.31 194 11259 1236 1734092
Hypothyroidism 672.96 41.31 204 11249 2356 1732972
Yellow skin 644.35 41.31 140 11313 331 1734997
Anaemia 576.12 41.31 374 11079 29083 1706245
Gastrointestinal stromal tumour 560.13 41.31 121 11332 275 1735053
Dehydration 558.83 41.31 306 11147 17352 1717976
Blood pressure increased 547.06 41.31 257 11196 10496 1724832
Ageusia 534.41 41.31 153 11300 1421 1733907
Weight decreased 527.53 41.31 322 11131 22431 1712897
Mucosal inflammation 511.27 41.31 187 11266 3982 1731346
Hair colour changes 484.22 41.31 110 11343 342 1734986
Osteonecrosis of jaw 476.18 41.31 179 11274 4124 1731204
Pleural effusion 463.81 41.31 232 11221 10878 1724450
Dry skin 456.93 41.31 167 11286 3545 1731783
Dyspepsia 436.66 41.31 175 11278 4810 1730518
Constipation 435.99 41.31 246 11207 14754 1720574
Pain in extremity 431.75 41.31 263 11190 18209 1717119
Abdominal pain 429.53 41.31 277 11176 21213 1714115
Glossodynia 429.12 41.31 109 11344 606 1734722
Pyrexia 404.40 41.31 364 11089 46036 1689292
Malaise 382.68 41.31 292 11161 29273 1706055
Epistaxis 374.81 41.31 183 11270 8123 1727205
White blood cell count decreased 374.78 41.31 213 11240 12936 1722392
General physical health deterioration 369.86 41.31 211 11242 12907 1722421
Dyspnoea 361.15 41.31 360 11093 51699 1683629
Pain 337.55 41.31 260 11193 26397 1708931
Rash 335.56 41.31 303 11150 38390 1696938
Neoplasm malignant 334.32 41.31 139 11314 4200 1731128
Blister 311.58 41.31 130 11323 3962 1731366
Blood creatinine increased 311.27 41.31 193 11260 13753 1721575
Skin exfoliation 301.97 41.31 131 11322 4404 1730924
Renal cancer metastatic 291.53 41.31 63 11390 143 1735185
Skin discolouration 268.48 41.31 106 11347 2790 1732538
Neutropenia 250.42 41.31 187 11266 18073 1717255
Abdominal discomfort 250.13 41.31 144 11309 8937 1726391
Ascites 248.56 41.31 122 11331 5464 1729864
Toxicity to various agents 247.83 41.31 226 11227 28915 1706413
Pneumonia 242.68 41.31 276 11177 45906 1689422
Renal failure 220.27 41.31 180 11273 19837 1715491
Second primary malignancy 217.63 41.31 70 11383 989 1734339
Gastrooesophageal reflux disease 199.28 41.31 99 11354 4548 1730780
Malignant neoplasm progression 198.46 41.31 147 11306 14011 1721317
Haemoglobin decreased 194.76 41.31 157 11296 16957 1718371
Bone marrow failure 191.61 41.31 100 11353 5100 1730228
Back pain 188.17 41.31 152 11301 16461 1718867
Dry mouth 187.68 41.31 90 11363 3823 1731505
Jaundice 171.82 41.31 98 11355 5964 1729364
Oedema peripheral 167.08 41.31 138 11315 15412 1719916
Cough 165.08 41.31 150 11303 19047 1716281
Abdominal pain upper 164.91 41.31 119 11334 10882 1724446
Dizziness 164.45 41.31 196 11257 34165 1701163
Haemoptysis 163.32 41.31 88 11365 4788 1730540
Proteinuria 159.83 41.31 73 11380 2771 1732557
Hyponatraemia 159.75 41.31 108 11345 8892 1726436
Acute kidney injury 156.90 41.31 193 11260 34751 1700577
Renal impairment 155.12 41.31 120 11333 12194 1723134
Disseminated intravascular coagulation 151.97 41.31 76 11377 3538 1731790
Blood thyroid stimulating hormone increased 151.02 41.31 47 11406 592 1734736
Confusional state 150.06 41.31 149 11304 21129 1714199
Pancytopenia 148.13 41.31 113 11340 11244 1724084
Impaired healing 144.29 41.31 66 11387 2513 1732815
Hyperkeratosis 142.32 41.31 45 11408 599 1734729
Pulmonary embolism 140.45 41.31 116 11337 12943 1722385
Leukopenia 139.23 41.31 97 11356 8383 1726945
Headache 138.62 41.31 180 11273 34196 1701132
Ejection fraction decreased 136.85 41.31 61 11392 2184 1733144
Flatulence 136.17 41.31 66 11387 2868 1732460
Haemorrhage 135.26 41.31 101 11352 9728 1725600
Sepsis 133.13 41.31 134 11319 19304 1716024
Abdominal distension 133.00 41.31 85 11368 6359 1728969
Haematuria 132.42 41.31 90 11363 7470 1727858
Cardiopulmonary failure 132.32 41.31 46 11407 835 1734493
Gastrointestinal haemorrhage 129.51 41.31 115 11338 14152 1721176
Gait disturbance 128.90 41.31 109 11344 12561 1722767
Mouth ulceration 127.59 41.31 54 11399 1701 1733627
Oedema 127.15 41.31 85 11368 6863 1728465
Arthralgia 125.85 41.31 142 11311 23302 1712026
Oral discomfort 121.84 41.31 38 11415 482 1734846
Chest pain 116.14 41.31 126 11327 19788 1715540
Pericardial effusion 115.78 41.31 62 11391 3328 1732000
Skin ulcer 115.35 41.31 58 11395 2730 1732598
Dysphagia 114.92 41.31 93 11360 10075 1725253
Gingival pain 111.81 41.31 34 11419 394 1734934
Interstitial lung disease 110.24 41.31 89 11364 9607 1725721
Haematemesis 106.16 41.31 64 11389 4313 1731015
Muscular weakness 105.91 41.31 89 11364 10160 1725168
Peripheral swelling 105.39 41.31 80 11373 7891 1727437
Cardiac failure 105.34 41.31 97 11356 12505 1722823
Skin disorder 104.40 41.31 50 11403 2114 1733214
Chills 103.64 41.31 93 11360 11594 1723734
Skin lesion 103.30 41.31 55 11398 2917 1732411
Erythema 101.11 41.31 100 11353 14088 1721240
Skin fissures 101.00 41.31 36 11417 705 1734623
Cholecystitis 96.51 41.31 43 11410 1537 1733791
Aortic dissection 94.32 41.31 31 11422 470 1734858
Blood lactate dehydrogenase increased 92.40 41.31 55 11398 3620 1731708
Hypotension 92.02 41.31 137 11316 29517 1705811
Rectal haemorrhage 90.00 41.31 63 11390 5479 1729849
Hypoglycaemia 88.66 41.31 74 11379 8364 1726964
Product use issue 87.65 41.31 74 11379 8497 1726831
Blood urea increased 87.04 41.31 58 11395 4653 1730675
Infection 85.98 41.31 86 11367 12274 1723054
Condition aggravated 85.47 41.31 111 11342 21039 1714289
Metastases to liver 84.59 41.31 44 11409 2223 1733105
Hypercalcaemia 83.22 41.31 41 11412 1845 1733483
Cerebral haemorrhage 82.96 41.31 63 11390 6214 1729114
Periorbital oedema 82.73 41.31 31 11422 703 1734625
Aspartate aminotransferase increased 82.58 41.31 79 11374 10677 1724651
Neutrophil count decreased 82.51 41.31 62 11391 6019 1729309
Nephrotic syndrome 81.59 41.31 37 11416 1379 1733949
Muscle spasms 81.09 41.31 81 11372 11540 1723788
Chromaturia 80.87 41.31 45 11408 2605 1732723
Contusion 80.77 41.31 58 11395 5251 1730077
Hypertensive crisis 78.92 41.31 37 11416 1490 1733838
Oropharyngeal pain 78.76 41.31 55 11398 4763 1730565
Metastases to lung 78.73 41.31 37 11416 1498 1733830
Syncope 77.94 41.31 87 11366 14082 1721246
Anal abscess 77.89 41.31 31 11422 831 1734497
Thyroid disorder 77.81 41.31 27 11426 487 1734841
Oral mucosal blistering 77.11 41.31 24 11429 302 1735026
Weight increased 77.11 41.31 78 11375 11279 1724049
Paraesthesia 76.92 41.31 75 11378 10376 1724952
Pruritus 75.91 41.31 110 11343 23112 1712216
Hyperaesthesia 75.63 41.31 29 11424 702 1734626
Face oedema 74.94 41.31 41 11412 2295 1733033
Alopecia 73.68 41.31 48 11405 3705 1731623
Respiratory failure 72.90 41.31 85 11368 14420 1720908
Feeling abnormal 72.74 41.31 75 11378 11091 1724237
Myocardial infarction 72.31 41.31 117 11336 27057 1708271
Hepatic function abnormal 72.16 41.31 61 11392 7013 1728315
Insomnia 71.38 41.31 89 11364 16187 1719141
Hypoalbuminaemia 71.23 41.31 34 11419 1426 1733902
Thyroid function test abnormal 69.34 41.31 20 11433 190 1735138
Pneumothorax 69.24 41.31 41 11412 2671 1732657
Pain in jaw 68.80 41.31 37 11416 2001 1733327
Tumour lysis syndrome 68.25 41.31 35 11418 1716 1733612
Fall 68.13 41.31 114 11339 27100 1708228
Intestinal perforation 67.89 41.31 34 11419 1585 1733743
Blood bilirubin increased 66.34 41.31 55 11398 6155 1729173
Multiple organ dysfunction syndrome 65.53 41.31 65 11388 9177 1726151
Red blood cell count decreased 64.77 41.31 44 11409 3642 1731686
Tongue discomfort 64.68 41.31 16 11437 78 1735250
Performance status decreased 64.67 41.31 26 11427 716 1734612
Product use in unapproved indication 64.48 41.31 65 11388 9357 1725971
Tumour haemorrhage 63.61 41.31 24 11429 555 1734773
Eating disorder 63.43 41.31 30 11423 1232 1734096
Lethargy 63.31 41.31 57 11396 7127 1728201
Hypogeusia 62.88 41.31 18 11435 166 1735162
Lacrimation increased 62.87 41.31 31 11422 1397 1733931
Hepatic failure 62.47 41.31 52 11401 5851 1729477
Blood sodium decreased 61.89 41.31 36 11417 2268 1733060
Musculoskeletal pain 60.67 41.31 48 11405 5026 1730302
Exposed bone in jaw 59.93 41.31 22 11431 470 1734858
Gingival bleeding 59.65 41.31 29 11424 1267 1734061
Blood glucose decreased 58.96 41.31 35 11418 2290 1733038
Diverticulitis 58.96 41.31 35 11418 2290 1733038
Hiccups 58.95 41.31 30 11423 1447 1733881
Glossitis 58.55 41.31 19 11434 276 1735052
Haemorrhoids 58.52 41.31 32 11421 1789 1733539
Myalgia 58.31 41.31 79 11374 15579 1719749
Neuropathy peripheral 58.18 41.31 61 11392 9192 1726136
Metastases to central nervous system 57.67 41.31 30 11423 1515 1733813
Intestinal obstruction 57.23 41.31 40 11413 3467 1731861
Renal cell carcinoma stage IV 57.22 41.31 12 11441 22 1735306
Malignant urinary tract neoplasm 57.22 41.31 12 11441 22 1735306
Urinary tract infection 56.94 41.31 63 11390 10090 1725238
Gastrointestinal toxicity 56.91 41.31 20 11433 375 1734953
Hyperbilirubinaemia 56.88 41.31 34 11419 2253 1733075
Eye swelling 56.49 41.31 32 11421 1917 1733411
Tongue blistering 56.16 41.31 15 11438 104 1735224
Somnolence 55.69 41.31 80 11373 16659 1718669
Oesophagitis 54.96 41.31 30 11423 1671 1733657
Bone pain 54.05 41.31 38 11415 3324 1732004
Generalised oedema 54.02 41.31 30 11423 1729 1733599
Cholecystitis acute 53.89 41.31 24 11429 856 1734472
Cardiac failure congestive 53.78 41.31 75 11378 15195 1720133
Thrombotic microangiopathy 53.72 41.31 27 11426 1268 1734060
Blood albumin decreased 53.07 41.31 29 11424 1619 1733709
Clear cell renal cell carcinoma 52.72 41.31 15 11438 135 1735193
Pancreatic neuroendocrine tumour 52.44 41.31 13 11440 64 1735264
Alanine aminotransferase increased 51.99 41.31 66 11387 12212 1723116
Hypoaesthesia 51.68 41.31 59 11394 9776 1725552
Thrombosis 51.66 41.31 52 11401 7469 1727859
Pneumatosis intestinalis 51.47 41.31 20 11433 502 1734826
Tumour necrosis 51.28 41.31 16 11437 203 1735125
Drug intolerance 51.26 41.31 47 11406 6015 1729313
Blood count abnormal 50.72 41.31 27 11426 1430 1733898
Lipase increased 50.70 41.31 28 11425 1596 1733732
Cerebrovascular accident 50.32 41.31 79 11374 17787 1717541
Gout 50.22 41.31 33 11420 2583 1732745
Therapy cessation 49.35 41.31 35 11418 3104 1732224
Blood alkaline phosphatase increased 49.31 41.31 43 11410 5152 1730176
Deep vein thrombosis 47.93 41.31 57 11396 9863 1725465
Feeding disorder 47.52 41.31 22 11431 860 1734468
Gastritis 47.27 41.31 34 11419 3083 1732245
Cardiac disorder 47.10 41.31 50 11403 7641 1727687
Cholangitis 47.01 41.31 24 11429 1165 1734163
Metastases to bone 46.26 41.31 27 11426 1711 1733617
Pulmonary oedema 46.08 41.31 46 11407 6540 1728788
Seizure 45.06 41.31 81 11372 20360 1714968
Cellulitis 44.93 41.31 45 11408 6423 1728905
Gastrointestinal disorder 44.46 41.31 39 11414 4709 1730619
Gingivitis 44.41 41.31 19 11434 614 1734714
Gastric disorder 44.33 41.31 27 11426 1851 1733477
Peritonitis 44.13 41.31 31 11422 2708 1732620
Hypophagia 43.78 41.31 34 11419 3463 1731865
Swelling 43.76 41.31 46 11407 6950 1728378
Mouth haemorrhage 43.65 41.31 21 11432 896 1734432
Blood urine present 43.42 41.31 27 11426 1921 1733407
Haematochezia 43.18 41.31 39 11414 4893 1730435
C-reactive protein increased 42.83 41.31 42 11411 5843 1729485
Haematotoxicity 42.77 41.31 21 11432 937 1734391
Wound 42.48 41.31 25 11428 1609 1733719
Skin toxicity 42.09 41.31 18 11435 581 1734747
Joint swelling 41.94 41.31 43 11410 6310 1729018
Vision blurred 41.68 41.31 49 11404 8374 1726954
Chronic kidney disease 41.51 41.31 36 11417 4281 1731047

Pharmacologic Action:

SourceCodeDescription
ATC L01XE04 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
ANTINEOPLASTIC AGENTS
OTHER ANTINEOPLASTIC AGENTS
Protein kinase inhibitors
FDA EPC N0000175605 Kinase Inhibitor
MeSH PA D020533 Angiogenesis Inhibitors
MeSH PA D000970 Antineoplastic Agents
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D006131 Growth Inhibitors
MeSH PA D006133 Growth Substances
MeSH PA D047428 Protein Kinase Inhibitors
CHEBI has role CHEBI:48422 angiogenesis inhibitor
CHEBI has role CHEBI:35610 antineoplastic agent
CHEBI has role CHEBI:50846 immunomodulator
CHEBI has role CHEBI:63726 neuroprotective agent

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Gastrointestinal stromal tumor indication 420120006 DOID:9253
Renal cell carcinoma indication 702391001 DOID:4450
Pancreatic Neuroendocrine Tumor indication
Acute hemorrhage contraindication 8573003
Hyperkalemia contraindication 14140009
Hyperbilirubinemia contraindication 14783006 DOID:2741
Torsades de pointes contraindication 31722008
Hyperthyroidism contraindication 34486009 DOID:7998
Hypothyroidism contraindication 40930008 DOID:1459
Hypokalemia contraindication 43339004
Bradycardia contraindication 48867003
Hepatic failure contraindication 59927004
Hemoptysis contraindication 66857006
Hypermagnesemia contraindication 66978005
Pancreatitis contraindication 75694006 DOID:4989
Heart failure contraindication 84114007 DOID:6000
Left heart failure contraindication 85232009
Prolonged QT interval contraindication 111975006
Seizure disorder contraindication 128613002
Hypomagnesemia contraindication 190855004
Decompensated cardiac failure contraindication 195111005
Disease of liver contraindication 235856003 DOID:409
Drug-induced hepatitis contraindication 235876009
Anemia contraindication 271737000 DOID:2355
Pregnancy, function contraindication 289908002
Thrombocytopenic disorder contraindication 302215000 DOID:1588
Thromboembolic disorder contraindication 371039008
Adrenal cortical hypofunction contraindication 386584007 DOID:10493
Surgical procedure contraindication 387713003
Breastfeeding (mother) contraindication 413712001
Congenital long QT syndrome contraindication 442917000
Hypertensive urgency contraindication 443482000
Posterior reversible encephalopathy syndrome contraindication 450886002

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 10.52 acidic
pKa2 11.68 acidic
pKa3 12.32 acidic
pKa4 9.32 Basic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
EQ 12.5MG BASE SUTENT CPPI CV N021938 Jan. 26, 2006 RX CAPSULE ORAL 7211600 Dec. 22, 2020 TREATMENT OF GASTROINTESTINAL STROMAL TUMOR WITH SUNITINIB
EQ 25MG BASE SUTENT CPPI CV N021938 Jan. 26, 2006 RX CAPSULE ORAL 7211600 Dec. 22, 2020 TREATMENT OF GASTROINTESTINAL STROMAL TUMOR WITH SUNITINIB
EQ 37.5MG BASE SUTENT CPPI CV N021938 March 31, 2009 RX CAPSULE ORAL 7211600 Dec. 22, 2020 TREATMENT OF GASTROINTESTINAL STROMAL TUMOR WITH SUNITINIB
EQ 50MG BASE SUTENT CPPI CV N021938 Jan. 26, 2006 RX CAPSULE ORAL 7211600 Dec. 22, 2020 TREATMENT OF GASTROINTESTINAL STROMAL TUMOR WITH SUNITINIB
EQ 12.5MG BASE SUTENT CPPI CV N021938 Jan. 26, 2006 RX CAPSULE ORAL 6573293 Feb. 15, 2021 ADJUVANT TREATMENT OF ADULT PATIENTS AT HIGH RISK OF RECURRENT RCC FOLLOWING NEPHRECTOMY
EQ 12.5MG BASE SUTENT CPPI CV N021938 Jan. 26, 2006 RX CAPSULE ORAL 6573293 Feb. 15, 2021 TREATMENT OF PROTEIN KINASE RELATED DISORDERS, SUCH AS GASTROINTESTINAL STROMAL TUMORS, RENAL CELL CARCINOMA AND ADVANCED PANCREATIC NEUROENDOCRINE TUMORS, WITH SUNITINIB
EQ 25MG BASE SUTENT CPPI CV N021938 Jan. 26, 2006 RX CAPSULE ORAL 6573293 Feb. 15, 2021 ADJUVANT TREATMENT OF ADULT PATIENTS AT HIGH RISK OF RECURRENT RCC FOLLOWING NEPHRECTOMY
EQ 25MG BASE SUTENT CPPI CV N021938 Jan. 26, 2006 RX CAPSULE ORAL 6573293 Feb. 15, 2021 TREATMENT OF PROTEIN KINASE RELATED DISORDERS, SUCH AS GASTROINTESTINAL STROMAL TUMORS, RENAL CELL CARCINOMA AND ADVANCED PANCREATIC NEUROENDOCRINE TUMORS, WITH SUNITINIB
EQ 37.5MG BASE SUTENT CPPI CV N021938 March 31, 2009 RX CAPSULE ORAL 6573293 Feb. 15, 2021 ADJUVANT TREATMENT OF ADULT PATIENTS AT HIGH RISK OF RECURRENT RCC FOLLOWING NEPHRECTOMY
EQ 37.5MG BASE SUTENT CPPI CV N021938 March 31, 2009 RX CAPSULE ORAL 6573293 Feb. 15, 2021 TREATMENT OF PROTEIN KINASE RELATED DISORDERS, SUCH AS GASTROINTESTINAL STROMAL TUMORS, RENAL CELL CARCINOMA AND ADVANCED PANCREATIC NEUROENDOCRINE TUMORS, WITH SUNITINIB
EQ 50MG BASE SUTENT CPPI CV N021938 Jan. 26, 2006 RX CAPSULE ORAL 6573293 Feb. 15, 2021 ADJUVANT TREATMENT OF ADULT PATIENTS AT HIGH RISK OF RECURRENT RCC FOLLOWING NEPHRECTOMY
EQ 50MG BASE SUTENT CPPI CV N021938 Jan. 26, 2006 RX CAPSULE ORAL 6573293 Feb. 15, 2021 TREATMENT OF PROTEIN KINASE RELATED DISORDERS, SUCH AS GASTROINTESTINAL STROMAL TUMORS, RENAL CELL CARCINOMA AND ADVANCED PANCREATIC NEUROENDOCRINE TUMORS, WITH SUNITINIB

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
EQ 12.5MG BASE SUTENT CPPI CV N021938 Jan. 26, 2006 RX CAPSULE ORAL Nov. 16, 2020 ADJUVANT TREATMENT OF ADULT PATIENTS AT HIGH RISK OF RECURRENT RENAL CELL CARCINOMA (RCC) FOLLOWING NEPHRECTOMY
EQ 25MG BASE SUTENT CPPI CV N021938 Jan. 26, 2006 RX CAPSULE ORAL Nov. 16, 2020 ADJUVANT TREATMENT OF ADULT PATIENTS AT HIGH RISK OF RECURRENT RENAL CELL CARCINOMA (RCC) FOLLOWING NEPHRECTOMY
EQ 37.5MG BASE SUTENT CPPI CV N021938 March 31, 2009 RX CAPSULE ORAL Nov. 16, 2020 ADJUVANT TREATMENT OF ADULT PATIENTS AT HIGH RISK OF RECURRENT RENAL CELL CARCINOMA (RCC) FOLLOWING NEPHRECTOMY
EQ 50MG BASE SUTENT CPPI CV N021938 Jan. 26, 2006 RX CAPSULE ORAL Nov. 16, 2020 ADJUVANT TREATMENT OF ADULT PATIENTS AT HIGH RISK OF RECURRENT RENAL CELL CARCINOMA (RCC) FOLLOWING NEPHRECTOMY
EQ 12.5MG BASE SUTENT CPPI CV N021938 Jan. 26, 2006 RX CAPSULE ORAL May 16, 2021 PEDIATRIC EXCLUSIVITY
EQ 25MG BASE SUTENT CPPI CV N021938 Jan. 26, 2006 RX CAPSULE ORAL May 16, 2021 PEDIATRIC EXCLUSIVITY
EQ 37.5MG BASE SUTENT CPPI CV N021938 March 31, 2009 RX CAPSULE ORAL May 16, 2021 PEDIATRIC EXCLUSIVITY
EQ 50MG BASE SUTENT CPPI CV N021938 Jan. 26, 2006 RX CAPSULE ORAL May 16, 2021 PEDIATRIC EXCLUSIVITY

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Proto-oncogene tyrosine-protein kinase receptor Ret Kinase INHIBITOR IC50 8.80 IUPHAR DRUG LABEL
Platelet-derived growth factor receptor beta Kinase INHIBITOR Kd 10.12 CHEMBL CHEMBL
Receptor-type tyrosine-protein kinase FLT3 Kinase INHIBITOR Kd 9.66 CHEMBL CHEMBL
Vascular endothelial growth factor receptor 2 Kinase INHIBITOR Kd 9.70 CHEMBL CHEMBL
Mast/stem cell growth factor receptor Kit Kinase INHIBITOR Kd 9.68 CHEMBL CHEMBL
Macrophage colony-stimulating factor 1 receptor Kinase INHIBITOR Kd 8.70 CHEMBL CHEMBL
Vascular endothelial growth factor receptor 3 Kinase INHIBITOR Ki 7.77 CHEMBL CHEMBL
Vascular endothelial growth factor receptor 1 Kinase INHIBITOR IC50 7.23 SCIENTIFIC LITERATURE DRUG LABEL
Platelet-derived growth factor receptor alpha Kinase INHIBITOR IC50 6.96 SCIENTIFIC LITERATURE DRUG LABEL
Serine/threonine-protein kinase DCLK1 Kinase Kd 6.43 CHEMBL
Muscle, skeletal receptor tyrosine-protein kinase Kinase Kd 6.31 CHEMBL
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Kinase IC50 4.89 CHEMBL
Mitogen-activated protein kinase 9 Kinase Kd 5.62 CHEMBL
Proto-oncogene tyrosine-protein kinase Src Kinase Kd 5.68 CHEMBL
Fibroblast growth factor receptor 3 Kinase Kd 6.54 CHEMBL
Calcium/calmodulin-dependent protein kinase type 1 Kinase Kd 6.01 CHEMBL
Serine/threonine-protein kinase 35 Kinase Kd 5.89 CHEMBL
Calcium/calmodulin-dependent protein kinase type IV Kinase Kd 6.05 CHEMBL
Serine/threonine-protein kinase BRSK1 Kinase Kd 5.46 CHEMBL
Fibroblast growth factor receptor 4 Kinase Kd 5.68 CHEMBL
SRSF protein kinase 1 Kinase Kd 6.60 CHEMBL
Dual specificity tyrosine-phosphorylation-regulated kinase 2 Kinase Kd 6.17 CHEMBL
Serine/threonine-protein kinase RIO3 Kinase Kd 5.42 CHEMBL
Hepatocyte growth factor receptor Kinase Kd 5.92 CHEMBL
Casein kinase I isoform epsilon Kinase Kd 7.89 CHEMBL
Myosin-IIIb Kinase Kd 5.35 CHEMBL
Dual specificity mitogen-activated protein kinase kinase 3 Kinase Kd 5.77 CHEMBL
Serine/threonine-protein kinase PAK 3 Kinase Kd 7.80 CHEMBL
Calcium/calmodulin-dependent protein kinase type II subunit beta Kinase Kd 5.85 CHEMBL
Tyrosine-protein kinase JAK2 Kinase Kd 6.39 CHEMBL
Ribosomal protein S6 kinase alpha-6 Kinase Kd 5.62 CHEMBL
MAP/microtubule affinity-regulating kinase 3 Kinase Kd 6.39 CHEMBL
Ribosomal protein S6 kinase alpha-1 Kinase Kd 7.02 CHEMBL
Serine/threonine-protein kinase NIM1 Kinase Kd 6.07 CHEMBL
Cyclin-G-associated kinase Kinase Kd 7.70 CHEMBL
Serine/threonine-protein kinase SBK1 Kinase Kd 6.70 CHEMBL
Mitogen-activated protein kinase kinase kinase 15 Kinase Kd 5.89 CHEMBL
Microtubule-associated serine/threonine-protein kinase 1 Kinase Kd 6.70 CHEMBL
Aurora kinase A Kinase Kd 5.77 CHEMBL
Dual specificity mitogen-activated protein kinase kinase 5 Kinase Kd 7.34 CHEMBL
Tyrosine-protein kinase JAK1 Kinase Kd 8.05 CHEMBL
Casein kinase I isoform delta Kinase Kd 7.82 CHEMBL
Tyrosine-protein kinase ITK/TSK Kinase Kd 7.89 CHEMBL
Homeodomain-interacting protein kinase 3 Kinase Kd 7.39 CHEMBL
Homeodomain-interacting protein kinase 2 Kinase Kd 7.51 CHEMBL
Serine/threonine-protein kinase pim-3 Kinase Kd 5.62 CHEMBL
Maternal embryonic leucine zipper kinase Kinase Kd 6.46 CHEMBL
Wee1-like protein kinase Kinase Kd 5.96 CHEMBL
Interferon-induced, double-stranded RNA-activated protein kinase Kinase Kd 6.17 CHEMBL
NUAK family SNF1-like kinase 1 Kinase Kd 7.32 CHEMBL
Serine/threonine-protein kinase BRSK2 Kinase Kd 5.96 CHEMBL
U4/U6 small nuclear ribonucleoprotein Prp4 Unclassified Kd 6.41 CHEMBL
Serine/threonine-protein kinase D1 Kinase Kd 6.51 CHEMBL
Mitogen-activated protein kinase kinase kinase 13 Kinase Kd 7.02 CHEMBL
Serine/threonine-protein kinase TBK1 Kinase Kd 6.92 CHEMBL
Serine/threonine-protein kinase ICK Kinase Kd 6.33 CHEMBL
Serine/threonine-protein kinase Nek7 Kinase Kd 5.39 CHEMBL
Mitogen-activated protein kinase kinase kinase kinase 1 Kinase Kd 7.80 CHEMBL
Serine/threonine-protein kinase/endoribonuclease IRE1 Kinase Kd 6.22 CHEMBL
MAP kinase-interacting serine/threonine-protein kinase 1 Kinase Kd 5.41 CHEMBL
MAP/microtubule affinity-regulating kinase 4 Kinase Kd 5.44 CHEMBL
Serine/threonine-protein kinase OSR1 Kinase Kd 6.28 CHEMBL
Tyrosine-protein kinase Fgr Kinase Kd 6.57 CHEMBL
Serine/threonine-protein kinase D3 Kinase Kd 6.55 CHEMBL
Serine/threonine-protein kinase Sgk3 Kinase Kd 6.66 CHEMBL
STE20/SPS1-related proline-alanine-rich protein kinase Kinase Kd 6.85 CHEMBL
Mitogen-activated protein kinase kinase kinase 7 Kinase Kd 7.03 CHEMBL
Dual specificity protein kinase CLK2 Kinase Kd 7.70 CHEMBL
G protein-coupled receptor kinase 7 Kinase Kd 6.74 CHEMBL
Myosin light chain kinase family member 4 Kinase Kd 7.82 CHEMBL
Tyrosine-protein kinase FRK Kinase Kd 6.28 CHEMBL
Homeodomain-interacting protein kinase 1 Kinase Kd 7.26 CHEMBL
Dual specificity protein kinase CLK1 Kinase Kd 7.66 CHEMBL
Dual specificity protein kinase TTK Kinase Kd 7.20 CHEMBL
Serine/threonine-protein kinase tousled-like 2 Kinase Kd 6.48 CHEMBL
Ephrin type-A receptor 3 Kinase Kd 5.68 CHEMBL
Serine/threonine-protein kinase 10 Kinase Kd 7.72 CHEMBL
Tyrosine-protein kinase Fer Kinase Kd 5.96 CHEMBL
Serine/threonine-protein kinase 16 Kinase Kd 6.60 CHEMBL
Serine/threonine-protein kinase 17B Kinase Kd 6.96 CHEMBL
Calcium/calmodulin-dependent protein kinase type II subunit gamma Kinase Kd 6.36 CHEMBL
Serine/threonine-protein kinase PLK4 Kinase Kd 6.72 CHEMBL
AP2-associated protein kinase 1 Kinase Kd 7.96 CHEMBL
Serine/threonine-protein kinase MARK2 Kinase Kd 6.51 CHEMBL
Tyrosine-protein kinase JAK3 Kinase Kd 5.92 CHEMBL
Ribosomal protein S6 kinase alpha-5 Kinase Kd 7.77 CHEMBL
Casein kinase II subunit alpha' Kinase Kd 6.80 CHEMBL
Tyrosine-protein kinase Yes Kinase Kd 6.92 CHEMBL
Serine/threonine-protein kinase 38 Kinase Kd 6.39 CHEMBL
Serine/threonine-protein kinase N2 Kinase Kd 5.89 CHEMBL
Potassium voltage-gated channel subfamily H member 2 Ion channel IC50 6.30 CHEMBL
Serine/threonine-protein kinase TAO1 Kinase Kd 6.05 CHEMBL
Tyrosine-protein kinase HCK Kinase Kd 6.06 CHEMBL
Aurora kinase C Kinase Kd 6.66 CHEMBL
Phosphorylase b kinase gamma catalytic chain, liver/testis isoform Kinase Kd 8.23 CHEMBL
Casein kinase I isoform gamma-1 Kinase Kd 6.03 CHEMBL
High affinity nerve growth factor receptor Kinase Kd 7 CHEMBL
Fibroblast growth factor receptor 1 Kinase Kd 6.28 CHEMBL
Fibroblast growth factor receptor 2 Kinase Kd 6.28 CHEMBL
Rho-associated protein kinase 1 Kinase Kd 6.34 CHEMBL
Ribosomal protein S6 kinase alpha-3 Kinase Kd 7.26 CHEMBL
Citron Rho-interacting kinase Kinase Kd 5.41 CHEMBL
Myosin-IIIa Kinase Kd 5.51 CHEMBL
Homeodomain-interacting protein kinase 4 Kinase Kd 6.80 CHEMBL
Ankyrin repeat and protein kinase domain-containing protein 1 Kinase Kd 6.51 CHEMBL
Serine/threonine-protein kinase 25 Kinase Kd 6.54 CHEMBL
Myosin light chain kinase, smooth muscle Kinase Kd 7.64 CHEMBL
Mitogen-activated protein kinase kinase kinase 4 Kinase Kd 5.48 CHEMBL
Mitogen-activated protein kinase kinase kinase kinase 5 Kinase Kd 7.39 CHEMBL
Serine/threonine-protein kinase 38-like Kinase Kd 6.01 CHEMBL
Serine/threonine-protein kinase DCLK2 Kinase Kd 5.57 CHEMBL
Misshapen-like kinase 1 Kinase Kd 7.54 CHEMBL
Casein kinase I isoform alpha-like Kinase Kd 6.26 CHEMBL
Leucine-rich repeat serine/threonine-protein kinase 2 Kinase Kd 7.12 CHEMBL
Serine/threonine-protein kinase PAK 6 Kinase Kd 5.62 CHEMBL
Interleukin-1 receptor-associated kinase 4 Kinase Kd 7.18 CHEMBL
Insulin receptor-related protein Kinase Kd 6.37 CHEMBL
BMP-2-inducible protein kinase Kinase Kd 8.26 CHEMBL
Serine/threonine-protein kinase pim-2 Kinase Kd 5.30 CHEMBL
Serine/threonine-protein kinase PAK 7 Kinase Kd 6.19 CHEMBL
Serine/threonine-protein kinase 17A Kinase Kd 9 CHEMBL
Insulin-like growth factor 1 receptor Kinase Kd 5.59 CHEMBL
Mitogen-activated protein kinase kinase kinase 11 Kinase Kd 5.89 CHEMBL
Ephrin type-A receptor 6 Kinase Kd 6.02 CHEMBL
Megakaryocyte-associated tyrosine-protein kinase Kinase Kd 5.11 CHEMBL
TRAF2 and NCK-interacting protein kinase Kinase Kd 7.60 CHEMBL
Calcium/calmodulin-dependent protein kinase kinase 2 Kinase Kd 5.82 CHEMBL
Ribosomal protein S6 kinase alpha-4 Kinase Kd 7.02 CHEMBL
Aurora kinase B Kinase Kd 6.42 CHEMBL
STE20-like serine/threonine-protein kinase Kinase Kd 7.25 CHEMBL
Dual specificity protein kinase CLK4 Kinase Kd 7.54 CHEMBL
MAP kinase-interacting serine/threonine-protein kinase 2 Kinase Kd 5.24 CHEMBL
Death-associated protein kinase 2 Kinase Kd 6.82 CHEMBL
Bone morphogenetic protein receptor type-1B Kinase Kd 5.62 CHEMBL
Non-receptor tyrosine-protein kinase TYK2 Kinase Kd 6.44 CHEMBL
Interleukin-1 receptor-associated kinase 1 Kinase Kd 7.85 CHEMBL
Serine/threonine-protein kinase 4 Kinase Kd 7.72 CHEMBL
Protein-tyrosine kinase 6 Kinase Kd 5.34 CHEMBL
Calcium/calmodulin-dependent protein kinase kinase 1 Kinase Kd 6.38 CHEMBL
Calcium/calmodulin-dependent protein kinase type 1D Kinase Kd 6.29 CHEMBL
Serine/threonine-protein kinase 3 Kinase Kd 7.25 CHEMBL
Calcium/calmodulin-dependent protein kinase type 1G Kinase Kd 6.36 CHEMBL
5'-AMP-activated protein kinase catalytic subunit alpha-1 Kinase Kd 7.72 CHEMBL
Serine/threonine-protein kinase Nek2 Kinase Kd 6.30 CHEMBL
Tyrosine-protein kinase Lyn Kinase Kd 6.57 CHEMBL
Ribosomal protein S6 kinase alpha-2 Kinase Kd 7.77 CHEMBL
Ephrin type-A receptor 5 Kinase Kd 5.92 CHEMBL
Serine/threonine-protein kinase ULK2 Kinase Kd 7.89 CHEMBL
Ephrin type-B receptor 1 Kinase Kd 6.32 CHEMBL
Phosphorylase b kinase gamma catalytic chain, skeletal muscle/heart isoform Kinase Kd 8.26 CHEMBL
Activated CDC42 kinase 1 Kinase Kd 5.66 CHEMBL
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform Kinase IC50 4.96 CHEMBL
Cyclin-dependent kinase 16 Kinase Kd 6.89 CHEMBL
Mitogen-activated protein kinase kinase kinase kinase 3 Kinase Kd 6.74 CHEMBL
Focal adhesion kinase 1 Kinase Kd 6.36 CHEMBL
Casein kinase II subunit alpha Kinase Kd 7.09 CHEMBL
RAC-beta serine/threonine-protein kinase Kinase Kd 5.57 CHEMBL
NT-3 growth factor receptor Kinase Kd 5.29 CHEMBL
Serine/threonine-protein kinase STK11 Kinase Kd 7.42 CHEMBL
Interleukin-1 receptor-associated kinase 3 Kinase Kd 6.03 CHEMBL
Calcium/calmodulin-dependent protein kinase type II subunit alpha Kinase Kd 7.10 CHEMBL
G protein-coupled receptor kinase 4 Kinase Kd 6.85 CHEMBL
Mitogen-activated protein kinase kinase kinase 2 Kinase Kd 7.24 CHEMBL
Serine/threonine-protein kinase ULK3 Kinase Kd 7.38 CHEMBL
Abelson tyrosine-protein kinase 2 Kinase Kd 6 CHEMBL
Serine/threonine-protein kinase MARK1 Kinase Kd 5.92 CHEMBL
Serine/threonine-protein kinase 26 Kinase Kd 6.47 CHEMBL
Serine/threonine-protein kinase PLK2 Kinase Kd 5.33 CHEMBL
Bone morphogenetic protein receptor type-2 Kinase Kd 6.24 CHEMBL
Protein-tyrosine kinase 2-beta Kinase Kd 7.09 CHEMBL
Tyrosine-protein kinase Blk Kinase Kd 7.19 CHEMBL
Serine/threonine-protein kinase LATS2 Kinase Kd 6.34 CHEMBL
Inhibitor of nuclear factor kappa-B kinase subunit alpha Kinase Kd 6.28 CHEMBL
Dual specificity tyrosine-phosphorylation-regulated kinase 1B Kinase Kd 5.64 CHEMBL
Inhibitor of nuclear factor kappa-B kinase subunit epsilon Kinase Kd 6.21 CHEMBL
Serine/threonine-protein kinase PRP4 homolog Kinase Kd 6.41 CHEMBL
SNF-related serine/threonine-protein kinase Kinase Kd 6.19 CHEMBL
Dual serine/threonine and tyrosine protein kinase Kinase Kd 5.89 CHEMBL
Ephrin type-B receptor 6 Kinase Kd 6.07 CHEMBL
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform Kinase IC50 4.92 CHEMBL
Serine/threonine-protein kinase SIK2 Kinase Kd 6.24 CHEMBL
Serine/threonine-protein kinase TAO3 Kinase Kd 6.68 CHEMBL
Casein kinase I isoform alpha Kinase Kd 7 CHEMBL
Tankyrase-2 Enzyme Kd 5.05 CHEMBL
Cyclin-dependent kinase 7 Kinase Kd 6.48 CHEMBL
Rho-associated protein kinase 2 Kinase Kd 6.85 CHEMBL
Serine/threonine-protein kinase 24 Kinase Kd 7.20 CHEMBL
Casein kinase I isoform gamma-3 Kinase Kd 6.62 CHEMBL
Death-associated protein kinase 1 Kinase Kd 6.92 CHEMBL
5'-AMP-activated protein kinase catalytic subunit alpha-2 Kinase Kd 7.05 CHEMBL
Tyrosine-protein kinase Fyn Kinase Kd 6.28 CHEMBL
Uncharacterized serine/threonine-protein kinase SBK3 Kinase Kd 5.72 CHEMBL
Hormonally up-regulated neu tumor-associated kinase Kinase Kd 6.30 CHEMBL
Discoidin domain-containing receptor 2 Kinase Kd 5.54 CHEMBL
Cyclin-dependent kinase 17 Kinase Kd 5.92 CHEMBL
Death-associated protein kinase 3 Kinase Kd 7.66 CHEMBL
Tyrosine-protein kinase receptor Tie-1 Kinase Kd 5.41 CHEMBL
Serine/threonine-protein kinase PAK 4 Kinase Kd 5.64 CHEMBL
Serine/threonine-protein kinase DCLK3 Kinase Kd 6.96 CHEMBL
Cyclin-dependent kinase 14 Kinase Kd 6.57 CHEMBL
Eukaryotic translation initiation factor 2-alpha kinase 4 Kinase Kd 6.74 CHEMBL
Dual specificity tyrosine-phosphorylation-regulated kinase 1A Kinase Kd 6.70 CHEMBL
Epithelial discoidin domain-containing receptor 1 Kinase Kd 5.70 CHEMBL
Cyclin-dependent kinase 18 Kinase Kd 5.77 CHEMBL
Mitogen-activated protein kinase kinase kinase kinase 4 Kinase Kd 6.85 CHEMBL
Serine/threonine-protein kinase LATS1 Kinase Kd 6.20 CHEMBL
Tyrosine-protein kinase receptor TYRO3 Kinase Kd 7.31 CHEMBL
Tyrosine-protein kinase Fes/Fps Kinase Kd 6.02 CHEMBL
Tyrosine-protein kinase Lck Kinase Kd 6.64 CHEMBL
Myosin light chain kinase 2, skeletal/cardiac muscle Kinase Kd 7.31 CHEMBL
Mitogen-activated protein kinase kinase kinase 9 Kinase Kd 5.47 CHEMBL
Leukocyte tyrosine kinase receptor Kinase Kd 5.74 CHEMBL
Mitogen-activated protein kinase kinase kinase 19 Kinase Kd 7.77 CHEMBL
Tyrosine-protein kinase receptor UFO Kinase Kd 8.05 CHEMBL
Phosphatidylinositol 5-phosphate 4-kinase type-2 beta Kinase Kd 7.41 CHEMBL
3-phosphoinositide-dependent protein kinase 1 Kinase Kd 5.46 CHEMBL
Serine/threonine-protein kinase D2 Kinase Kd 6.42 CHEMBL
BDNF/NT-3 growth factors receptor Kinase Kd 6.23 CHEMBL
NUAK family SNF1-like kinase 2 Kinase Kd 6.82 CHEMBL
Protein delta homolog 1 Unclassified Kd 7 CHEMBL
SRSF protein kinase 2 Kinase Kd 6.72 CHEMBL
Dual specificity mitogen-activated protein kinase kinase 2 Kinase Kd 6.96 CHEMBL
Dual specificity mitogen-activated protein kinase kinase 4 Kinase Kd 6.15 CHEMBL
Serine/threonine-protein kinase tousled-like 1 Kinase Kd 6.13 CHEMBL
SRSF protein kinase 3 Kinase Kd 7.23 CHEMBL
Dual specificity mitogen-activated protein kinase kinase 6 Kinase Kd 5.28 CHEMBL
ALK tyrosine kinase receptor Kinase Kd 6.77 CHEMBL
Mitogen-activated protein kinase kinase kinase 12 Kinase Kd 7 CHEMBL
Myosin light chain kinase 3 Kinase Kd 7.64 CHEMBL
Receptor-interacting serine/threonine-protein kinase 1 Kinase Kd 6.43 CHEMBL
Phosphatidylinositol 4-phosphate 5-kinase type-1 alpha Kinase Kd 5.27 CHEMBL
Mitogen-activated protein kinase kinase kinase 3 Kinase Kd 6.66 CHEMBL
Cyclin-dependent-like kinase 5 Kinase Kd 5.16 CHEMBL
Serine/threonine-protein kinase RIO1 Kinase Kd 7.46 CHEMBL
Cyclin-dependent kinase 4 Kinase Kd 5.70 CHEMBL
Serine/threonine-protein kinase RIO2 Kinase Kd 7.31 CHEMBL
Ribosomal protein S6 kinase beta-1 Kinase Kd 7.32 CHEMBL
Serine/threonine-protein kinase ULK1 Kinase Kd 7.64 CHEMBL
Serine/threonine-protein kinase 33 Kinase Kd 7.77 CHEMBL
Serine/threonine-protein kinase Chk2 Kinase Kd 8.15 CHEMBL
Casein kinase I isoform gamma-2 Kinase Kd 6.96 CHEMBL
Testis-specific serine/threonine-protein kinase 1 Kinase Kd 5.20 CHEMBL
Calcium/calmodulin-dependent protein kinase type II subunit delta Kinase Kd 6.38 CHEMBL
Serine/threonine-protein kinase Chk1 Kinase Kd 6.52 CHEMBL
Receptor-interacting serine/threonine-protein kinase 4 Kinase Kd 5.68 CHEMBL
Serine/threonine-protein kinase N1 Kinase Kd 6.15 CHEMBL
Mitogen-activated protein kinase kinase kinase kinase 2 Kinase Kd 7.48 CHEMBL
Serine/threonine-protein kinase SIK1 Kinase Kd 5.49 CHEMBL
Protein kinase C alpha type Kinase Kd 5.22 CHEMBL
Tyrosine-protein kinase Mer Kinase Kd 7.59 CHEMBL
Mitogen-activated protein kinase 7 Kinase Kd 5 CHEMBL
Non-receptor tyrosine-protein kinase TNK1 Kinase Kd 6.17 CHEMBL
Ephrin type-B receptor 4 Kinase Kd 5.51 SCIENTIFIC LITERATURE
Ephrin type-A receptor 7 Kinase Kd 5.62 SCIENTIFIC LITERATURE
Rhodopsin kinase Kinase Kd 6.54 CHEMBL
Tyrosine-protein kinase BTK Kinase Kd 5.68 CHEMBL
Insulin receptor Kinase AGONIST Kd 6.74 CHEMBL
Mitogen-activated protein kinase 10 Kinase Kd 5.37 CHEMBL
Dual specificity mitogen-activated protein kinase kinase 1 Kinase Kd 6.89 CHEMBL
Cyclin-dependent kinase-like 2 Kinase Kd 5.96 CHEMBL
Tyrosine-protein kinase ABL1 Kinase Kd 7.26 CHEMBL
Epidermal growth factor receptor Kinase Kd 6.07 CHEMBL
Protein kinase C theta type Kinase Kd 5.37 CHEMBL
Proto-oncogene tyrosine-protein kinase Src Kinase IC50 6.26 CHEMBL
Myosin light chain kinase, smooth muscle Kinase Kd 7.64 CHEMBL
Serine/threonine-protein kinase ULK3 Kinase Kd 6.96 CHEMBL
Serine/threonine-protein kinase 3 Kinase Kd 6.80 CHEMBL
Serine/threonine-protein kinase PknB Kinase Kd 7.06 CHEMBL
Calcium-dependent protein kinase 1 Kinase Kd 5.89 CHEMBL

External reference:

IDSource
D000077210 MESH_DESCRIPTOR_UI
4025079 VUID
N0000175350 NUI
C1176020 UMLSCUI
D06402 KEGG_DRUG
421448007 SNOMEDCT_US
357977 RXNORM
421192001 SNOMEDCT_US
4025079 VANDF
d05717 MMSL
011192 NDDF
CHEMBL535 ChEMBL_ID
CHEMBL1567 ChEMBL_ID
LVX8N1UT73 UNII
341031-54-7 SECONDARY_CAS_RN
8646 INN_ID
B49 PDB_CHEM_ID
DB01268 DRUGBANK_ID
CHEBI:38940 CHEBI
5329102 PUBCHEM_CID
5713 IUPHAR_LIGAND_ID

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
SUTENT HUMAN PRESCRIPTION DRUG LABEL 1 0069-0550 CAPSULE 12.50 mg ORAL NDA 20 sections
SUTENT HUMAN PRESCRIPTION DRUG LABEL 1 0069-0770 CAPSULE 25 mg ORAL NDA 20 sections
SUTENT HUMAN PRESCRIPTION DRUG LABEL 1 0069-0830 CAPSULE 37.50 mg ORAL NDA 20 sections
SUTENT HUMAN PRESCRIPTION DRUG LABEL 1 0069-0980 CAPSULE 50 mg ORAL NDA 20 sections